2 completed, 1 recruiting. .
Follow Adelphi Real World: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Treatment Effectiveness in People With axSpA or PsA Starting Treatment With Bimekizumab, Risankizumab, Guselkumab, Upadacitinib, or a TNF Inhibitor observational study - Axial Spondylarthritis (axSpA), Psoriatic Arthritis (PsA) | Recruiting | Adelphi Real World | 700 | 2025-07-07 | 2026-10-27 | |
| Adelphi Primary Sjogren's Syndrome (pSS) Disease Specific Programme (DSP) Interview, PSC questionnaire, PRFs - Sjogren's Syndrome | Completed | GlaxoSmithKline | 2223 | 2018-06-13 | 2019-01-23 | |
| A Comparison of Patients on AVAMYS ® Versus NASONEX (A Trade Mark of Schering Corporation) and FLIXONASE ® on Key Health Outcome Measures Fluticasone furoate, mometasone furoate, fluticasone propionate - Rhinitis, Allergic, Perennial | Completed | GlaxoSmithKline | 540 | 2009-07-10 | 2017-08-14 |
Arthritis, Psoriatic (1) · Rhinitis, Allergic (1) · Rhinitis, Allergic, Perennial (1) · Sjogren's Syndrome (1)
Fluticasone (1) · Interviews as Topic (1) · Mometasone Furoate (1) · Observation (1) · fluticasone furoate (1)
United Kingdom (2)